Rob van Maanen
Directeur Technique/Scientifique/R&D chez BIOPHYTIS S.A.
Fortune : 171 $ au 30/04/2024
Profil
Rob van Maanen is currently the Chief Medical Officer at Biophytis SA since 2021.
Prior to this, he worked as the Senior Director-Medical at Astellas BV and as the Chief Medical Officer at Khondrion BV.
He holds an MBA from the University of Amsterdam and a doctorate from the University of Utrecht.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOPHYTIS SA
0,01% | 29/02/2024 | 75 983 ( 0,01% ) | 171 $ | 30/04/2024 |
Postes actifs de Rob van Maanen
| Sociétés | Poste | Début |
|---|---|---|
| BIOPHYTIS S.A. | Directeur Technique/Scientifique/R&D | 09/09/2021 |
Anciens postes connus de Rob van Maanen
| Sociétés | Poste | Fin |
|---|---|---|
Astellas BV
 Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The company is based in Leiden, Netherlands. | Directeur Technique/Scientifique/R&D | - |
Khondrion BV
 Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Directeur Technique/Scientifique/R&D | - |
Formation de Rob van Maanen
| University of Utrecht | Doctorate Degree |
| University of Amsterdam | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOPHYTIS S.A. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Khondrion BV
Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Health Technology |
Astellas BV
Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The company is based in Leiden, Netherlands. | Finance |
